Zimmer Biomet Holdings, Inc. (ZBH) Fundamental Analysis: Bull vs. Bear Case

ZBH

Zimmer Biomet Holdings, Inc.

Fundamental data last updated:November 14, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NYSE

County of HQ

United States

Next Earnings Date

02/09/2027

Business Summary

Zimmer Biomet operates with a strong competitive moat, primarily through its extensive portfolio of orthopedic and surgical products. The company generates cash by providing essential medical devices that are critical to healthcare providers, ensuring recurring revenue streams. Its customer lock-in is achieved through high switching costs and long-term contracts with hospitals and clinics. By continuously innovating and maintaining high-quality standards, Zimmer Biomet fortifies its market position against new entrants.

VALUATION

P/E

26.90 Market Cap ($M USD)

$20.37B

Forward P/E

12.49 PEG

5.89 PRICE TO SALES

2.38 PRICE TO BOOK

1.60 EV / EBITDA

12.02 5-Year Average P/E

Free Cash Flow Yield

8.13%

DCF Value

$361.99

Graham Number

$77.82

Price to FCF

12.30 EV to FCF

16.58 Earnings Yield

3.77%

FCF Yield

8.13%

DIVIDEND

Yield

0.90%

Annual Payout

$0.96

Payout Ratio

24.33%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$4.03

Next Year EPS Growth Estimate

$8.55

Next Year Revenue Growth Estimate

$8.61B

Return on Equity (ROE)

6.05%

FREE CASH FLOW

Operating Margin

15.11%

Debt-to-Equity

0.59 Piotroski F-Score

7 Altman Z-Score

2.45 Return on Invested Capital (ROIC)

5.28%

Current Ratio

1.46 Quick Ratio

0.79 Net Debt to EBITDA

3.11 Interest Coverage

4.49 Gross Profit margin

69.68%

FCF PER SHARE

$8.70

REVENUE PER SHARE

$44.99

Gainseekers Quantitative Analysis

Summary

The market seems to have mispriced Zimmer Biomet Holdings, Inc., given its DCF value significantly outstrips the recent trading price. With a Forward P/E of 12.49, the stock appears undervalued relative to its earnings potential, especially when juxtaposed against a robust EPS growth estimate. However, the Altman Z-score of 2.45 suggests caution, indicating moderate financial distress risk. The Earnings Yield of 3.77% is not particularly enticing, hinting at limited immediate upside unless growth accelerates. Overall, while the valuation metrics suggest potential, the financial health is not without its concerns.

AI Exposure / Tech Reliance

In the Medical Devices industry, Zimmer Biomet is well-positioned to leverage AI and tech advancements to enhance precision and efficiency in surgical procedures. The company's focus on innovation could drive product differentiation and improve patient outcomes. However, the rapid pace of technological change demands continuous investment to maintain its competitive edge.

The Bull Case

For the discerning GARP investor, Zimmer Biomet offers compelling strengths. A Piotroski F-Score of 7 indicates solid financial health, while a respectable ROIC of 5.28% reflects efficient capital allocation. The Free Cash Flow Yield of 8.13% underscores the company's ability to generate cash, supporting its pricing power and operational resilience. With a Gross Profit Margin of nearly 70%, Zimmer Biomet demonstrates robust cost management and potential for sustained profitability.

The Bear Case

Despite its strengths, Zimmer Biomet faces notable challenges. The Forward PEG ratio of 5.89 suggests the stock is priced for high growth, which may not materialize given its current execution. Trading close to its 52-week high, the stock appears technically overextended, raising concerns about near-term valuation risk. Additionally, a Price to Book ratio of 1.60 could deter value investors seeking deeper discounts. The company's Net Debt to EBITDA ratio of 3.11 also signals leverage concerns that could impact future flexibility.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$109.11

Institutional Ownership %

1-Year Beta

0.47 Insider Buying % (6 Mo)

Distance to 52-Week High

5.38%

Distance to 52-Week Low

25.92%

EARNINGS SURPRISE %

1.06%

50-DAY SMA

$95.12

200-DAY SMA

$92.03

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.